Guidance, NICE advice and quality standards in development | Guidance

Showing 121 to 130 of 392

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults	Interventional procedures guidance	9 January 2025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]	Technology appraisal guidance	11 December 2024
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	23 July 2025
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma	Interventional procedures guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]	Technology appraisal guidance	4 June 2025
Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338	Technology appraisal guidance	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]	Technology appraisal guidance	27 November 2024